Skip to search formSkip to main contentSkip to account menu

dalbavancin

Known as: dalbavancin [Chemical/Ingredient], Ristomycin A Aglycone, 5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-(2-deoxy-2-((10-methyl-1-oxoundecyl)amino)-beta-D-glucopyranuronosyl)-38-(((3-(dimethylamino)propyl)amino)carbonyl)-42-O-alpha-D-mannopyranosyl-N15-methyl-, dalbavancin B0 
A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
  • 2016
  • Corpus ID: 26115888
Vancomycin and teicoplanin, two glycopeptides, are intravenous antibiotics of choice for severe cutaneous infections possibly due… 
Review
2015
Review
2015
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of… 
2014
2014
An organization best known for setting standards for the electronic exchange of pharmacy data released recommendations in April… 
2010
2010
Background/Aims: Knowledge of dalbavancin renal replacement therapy (RRT) disposition is vital to ensure appropriate dosing. In… 
2008
2008
En los ultimos anos se han desarrollado 6 nuevos antibioticos activos frente a bacterias grampositivas, 3 de los cuales ya estan… 
Review
2008
Review
2008
Severe infections associated with gram-positive organisms such as Staphylococcus aureus contribute to significant morbidity and… 
2006
2006
Dalbavancin (Pfizer) is a new lipoglycopeptide antibiotic in phase 3 trials for the treatment of resistant gram-positive… 
Review
2005
Review
2005
Abstract Dalbavancin is a bactericidal dimethylaminopropyl amide glycopeptide derivative possessing an extended serum elimination… 
2004
2004
The glycopeptide antibiotic A40926 is produced by the actinomycete strain ATCC 39727, originally classified, on the basis of…